Biotech News

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal (MDGL)MadrigalCompany update

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2026 and November 14, 2026 to a total of 23 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Related news

Madrigal

MASH-Focused Biopharmaceutical Company Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation. The company is building a specialized commercial and clinical-development organization around therapies that...

Recent company news

Stock data

Close
396.74 USD
Market cap
10.44B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States